Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$42M
- −35.0% YoY · −13.2% QoQ
- EPS (diluted)
- −$0.52
- −40.5% YoY · −15.6% QoQ
Source: XBRL data from the Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 10-Q on SEC EDGAR. USD.
Atea Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 in both quarters; no product sales since inception
- Net loss $42.0M vs $31.2M YoY; operating loss $45.6M vs $37.2M
- R&D expense $38.3M vs $26.2M; HCV costs $30.2M vs $8.6M
- Cash, equivalents, securities $329.3M at September 30; operating cash use $103.8M nine months
- Share repurchases $11.4M this quarter; 3,054,195 shares retired
Risk Factors
- COVID-19 program discontinuation after SUNRISE-3 failed its primary endpoint in September 2024
- HCV regimen remains dependent on successful Phase 3 trials before regulatory submission
- Regulatory approval requires extensive clinical evidence and compliance with cGMP manufacturing standards
- Net loss $113.5 million and accumulated deficit $477.7 million as of September 30, 2025
- Share Repurchase Program consumed $25 million, increasing pressure for future financing needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atea Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.